Allied Market Research

2024

Anti-oral Mucositis Drug Market

Anti-Oral Mucositis Drug Market Size, Share, Competitive Landscape and Trend Analysis Report by Type (Mouthwash, Pain Control Medication, Other) and by Distribution Channel (Retail Pharmacy, Online Pharmacy, Hospital Pharmacy): Global Opportunity Analysis and Industry Forecast, 2023-2032

Select an option
Author's: | Roshan Deshmukh
Publish Date:

Get Sample to Email

Oral mucositis is a common complication caused of cancer treatments, including radiotherapy and chemotherapy. Chemotherapy leads to tear down of epithelial cells lining around the gastro intestinal tract, thus leaving the mucosal tissue wide open for array of infections. The disease may lead to severe pain and open sores among other complications. Symptoms associated with oral mucositis include blood in the mouth, swollen gums, and mouth sores.

COVID-19 Impact Analysis

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness a significant growth in the future, owing to the demand for vaccine and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the anti-oral mucositis drug market.

Top Impacting Factors

  • Rise in the prevalence of cancer incidents among geriatric population subsequently leads to rise in demand for oral-mucositis drugs, which is likely to drive market growth. The trend is anticipated to further boost the market in regions with ageing population, including Japan and China.
  • Oral-mucositis is characterized by brutal oral pain and ulcers. This creates the need for development of advanced therapeutics for quick and efficient cure from the acute pain, thus driving market growth for anti-oral mucositis drugs.
  • Globalization and increase of global and regional trade has led to poor lifestyle regimes leading to bad oral hygiene and rise in the number of oral cavity infections. This, in turn, combined with shift of consumer preferences toward a more health-conscious life is anticipated to boost demand for oral hygiene mouthwashes and injectable.
  • However, high cost of diagnosis and treatment associated with oral mucositis may hamper the growth in regions with underdeveloped and low income level population groups. This may lead to lower penetration in regions such as Africa and the Middle East.
  • In addition, complete shift of healthcare infrastructure in getting rid of COVID-19 has resulted in product launch delays, design & development cancellations, and clinical trial skips. This is likely to restrain or at least slow down the growth of anti-oral mucositis products.

Key Market Trends

  •  North America is anticipated to witness huge market traction, owing to rising cases of cancer patients being diagnosed coupled with growing demand for new age therapeutics for quick and efficient treatment of oral pain and related side effects.
  • Recently, Food and Drug Administration granted permission for fast track launch of SGX942 (Soligenix, Inc.) for patients suffering from oral mucositis in combination with neck and head cancer.
  • Globalization and increase of global and regional trade has led to poor lifestyle regimes leading to bad oral hygiene and rise in the number of oral cavity infections. This is more prevalent among population base of countries with large trade influx, including the U.S., China, and India.
  • The market is witnessing a huge shift toward demand for natural products for treatment of oral mucositis. This is attributed to reduction in the volume of side effects these products have on oral hygiene and thus has led to influx of key player investments in research and development of these natural products. Few of these products include Calendula Officinalis, Matricaria Chamomilla, and aloe vera.
  • Food and Drug Administration (FDA) has recently approved palifermin manufactured by Amgen Inc. for treatment of oral mucositis in patients suffering from cancer and undergoing bone marrow transplant.
  • Integration of new age technology has been on the radar of various industries, and under this, chemo mouthpiece was recently launched, which provides a safe, reliable, and easy-to-administer cryotherapy medical device to minimize effects of oral mucositis caused due to chemotherapy.
  • Gelx was recently launched by BMG Pharma as a potent alternative against oral mucositis. The product allows an added advantage of carrying out chemotherapy more efficiently without being worried about developing oral mucositis in the process.

Key Benefits of the Report

  • This study presents the analytical depiction of the anti-oral mucositis drug industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the anti-oral mucositis drug market share.
  • The current market is quantitatively analyzed to highlight the market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed analysis depending on competitive intensity and how the competition will take shape in the coming years.

Questions Answered in the Anti-Oral Mucositis Drug Report

  • Which are the leading players active in the anti-oral mucositis drug market?
  • How is each segment of the market expected to grow during the forecast period?
  • What are the adoption trends for the anti-oral mucositis drug market in emerging economies and established economies across the world?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What future projections would help in taking further strategic steps?
  • What are the impacts of COVID-19 in the industry?
  • What is anti-oral mucositis drug?
  • What is the anti-oral mucositis drug market prediction in the future?
  • What are the current trends and predicted trends?

Anti-Oral Mucositis Drug Market Report Highlights

Aspects Details
Anti-Oral Mucositis Drug Market By Type
By Type
  • Mouthwash
  • Pain Control Medication
  • Other
Anti-Oral Mucositis Drug Market By Distribution Channel
By Distribution Channel
  • Retail Pharmacy
  • Online Pharmacy
  • Hospital Pharmacy
Anti-Oral Mucositis Drug Market By Region
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players
Key Market Players

Cellceutix, Kinnear Pharmaceuticals, Onxeo S.A., Innovation Pharmaceuticals, Izun Pharma, Oragenics, Himalaya, Soligenix, Shoreline Pharmaceutical, Amang Pharmaceuticals

Loading Table Of Content...

Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?

Anti-Oral Mucositis Drug Market

Global Opportunity Analysis and Industry Forecast, 2023-2032